Seguir
Eric Letouzé
Eric Letouzé
Senior Researcher, INSERM U1162
Dirección de correo verificada de inserm.fr
Título
Citado por
Citado por
Año
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
K Schulze, S Imbeaud, E Letouzé, LB Alexandrov, J Calderaro, ...
Nature genetics 47 (5), 505-511, 2015
16302015
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
C Guichard, G Amaddeo, S Imbeaud, Y Ladeiro, L Pelletier, IB Maad, ...
Nature genetics 44 (6), 694-698, 2012
15292012
SDH mutations establish a hypermethylator phenotype in paraganglioma
E Letouzé, C Martinelli, C Loriot, N Burnichon, N Abermil, C Ottolenghi, ...
Cancer cell 23 (6), 739-752, 2013
7472013
Integrated genomic characterization of adrenocortical carcinoma
G Assié, E Letouzé, M Fassnacht, A Jouinot, W Luscap, O Barreau, ...
Nature genetics 46 (6), 607-612, 2014
6402014
Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification
J Calderaro, G Couchy, S Imbeaud, G Amaddeo, E Letouzé, JF Blanc, ...
Journal of hepatology 67 (4), 727-738, 2017
5852017
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
JC Nault, S Datta, S Imbeaud, A Franconi, M Mallet, G Couchy, E Letouzé, ...
Nature genetics 47 (10), 1187-1193, 2015
4922015
DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma
A Villanueva, A Portela, S Sayols, C Battiston, Y Hoshida, ...
Hepatology 61 (6), 1945-1956, 2015
3812015
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype
S Rebouissou, I Bernard-Pierrot, A de Reyniès, ML Lepage, C Krucker, ...
Science translational medicine 6 (244), 244ra91-244ra91, 2014
3632014
Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation
JC Nault, G Couchy, C Balabaud, G Morcrette, S Caruso, JF Blanc, ...
Gastroenterology 152 (4), 880-894. e6, 2017
3562017
Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation
C Pilati, E Letouzé, JC Nault, S Imbeaud, A Boulai, J Calderaro, ...
Cancer cell 25 (4), 428-441, 2014
2652014
Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression
S Rebouissou, A Franconi, J Calderaro, E Letouzé, S Imbeaud, C Pilati, ...
Hepatology 64 (6), 2047-2061, 2016
2542016
Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis
E Letouzé, J Shinde, V Renault, G Couchy, JF Blanc, E Tubacher, ...
Nature communications 8 (1), 1315, 2017
2462017
Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas
LJ Castro-Vega, E Letouzé, N Burnichon, A Buffet, PH Disderot, E Khalifa, ...
Nature communications 6 (1), 6044, 2015
1912015
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma
J Hadoux, J Favier, JY Scoazec, S Leboulleux, A Al Ghuzlan, ...
International Journal of Cancer 135 (11), 2711-2720, 2014
1852014
Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma
N Burnichon, A Buffet, B Parfait, E Letouzé, I Laurendeau, C Loriot, ...
Human molecular genetics 21 (26), 5397-5405, 2012
1642012
Oncometabolites‐driven tumorigenesis: from genetics to targeted therapy
A Morin, E Letouzé, AP Gimenez‐Roqueplo, J Favier
International journal of cancer 135 (10), 2237-2248, 2014
1582014
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response
S Caruso, AL Calatayud, J Pilet, T La Bella, S Rekik, S Imbeaud, ...
Gastroenterology 157 (3), 760-776, 2019
1542019
Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma
JC Nault, Y Martin, S Caruso, TZ Hirsch, Q Bayard, J Calderaro, C Charpy, ...
Hepatology 71 (1), 164-182, 2020
1522020
Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas
C Pilati, J Shinde, LB Alexandrov, G Assié, T André, Z Hélias‐Rodzewicz, ...
The Journal of pathology 242 (1), 10-15, 2017
1492017
Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress
Q Bayard, L Meunier, C Peneau, V Renault, J Shinde, JC Nault, I Mami, ...
Nature Communications 9 (1), 5235, 2018
1422018
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20